Myriad Genetics (NASDAQ:MYGN) announced it has appointed Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.
Mr. Donnelly brings more than 20 years of leadership experience in healthcare, diagnostics, and medical technology to the role.
In a statement, Sam Raha, incoming president and CEO of Myriad, said, “Bring brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution. He will be a critical member of our leadership team and will play an instrumental role in scaling our business, accelerating product adoption, and driving sustained profitable growth.”
Mr. Donnelly commented, “I’m thrilled to join Myriad Genetics, which has such a deep commitment to advancing genetic insights and plays a critical role in empowering patients, physicians, and partners with the information needed to improve health outcomes. I look forward to working alongside this talented team to expand our impact, foster innovation, and accelerate the company’s growth while staying true to Myriad’s mission of advancing health and well-being for all.”
